DIABETES DRUG CUTS YOUR WEIGHT BY 20%!
Now big pharma wants to make it a diet product
ABRAND-NEW diabetes drug is being hailed as a potential game changer in the battle against the bulge after a recent study showed the injectable helps patients safely shed as much as 20 percent of their body weight!
Yale University researchers followed patients who were either medically obese or had at least one weight-related health condition for a 72-week trial involving the medication tirzepatide.
Currently sold under the Mounjaro brand name, the once-a-week shot mimics the effects of two hormones, which help control blood sugar and send fullness signals from the gut to the brain.
Previous diabetes-related trials found users of the prescription medication, which was approved by the FDA in May, often ate less and slimmed down.
But in the latest nondiabetic analysis, scientists say those who took 15 mg jabs — the highest studied dose — experienced an average weight loss of 52 pounds!
Researchers also discovered nine out of ten participants dropped flab and more than half lost a whopping 20 percent of their total weight!
And almost everyone on the drug experienced improved blood sugar, blood pressure and cholesterol levels.
Tirzepatide has a retail cost of nearly $1,000 for a fourweek supply and is currently only approved to treat type 2 diabetes. But manufacturer Eli Lilly plans to pitch the drug to the FDA as a weight-loss aid.
Yale’s Dr. Ania Jastreboff says, “We should treat obesity as we treat any chronic disease — with effective and safe approaches which target underlying disease mechanisms — and these results underscore that tirzepatide may be doing just that.”